Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors ; volume:7 ; number:1 ; day:24 ; month:1 ; year:2019 ; pages:1-11 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (24.1.2019), 1-11, 12.2019
- Urheber
-
Conroy, Jeffrey M.
Pabla, Sarabjot
Nesline, Mary K.
Glenn, Sean T.
Papanicolau-Sengos, Antonios
Burgher, Blake
Andreas, Jonathan
Giamo, Vincent
Wang, Yirong
Lenzo, Felicia L.
Bshara, Wiam
Khalil, Maya
Dy, Grace K.
Madden, Katherine G.
Shirai, Keisuke
Dragnev, Konstantin
Tafe, Laura J.
Zhu, Jason
Labriola, Matthew
Marin, Daniele
McCall, Shannon J.
Clarke, Jeffrey
George, Daniel J.
Zhang, Tian
Zibelman, Matthew
Ghatalia, Pooja
Araujo-Fernandez, Isabel
Cruz-Merino, Luis de la
Singavi, Arun
George, Ben
MacKinnon, Alexander C.
Thompson, Jonathan
Singh, Rajbir
Jacob, Robin
Kasuganti, Deepa
Shah, Neel
Day, Roger
Galluzzi, Lorenzo
Gardner, Mark
Morrison, Carl
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0489-5
- URN
-
urn:nbn:de:101:1-2019030121485504192986
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Conroy, Jeffrey M.
- Pabla, Sarabjot
- Nesline, Mary K.
- Glenn, Sean T.
- Papanicolau-Sengos, Antonios
- Burgher, Blake
- Andreas, Jonathan
- Giamo, Vincent
- Wang, Yirong
- Lenzo, Felicia L.
- Bshara, Wiam
- Khalil, Maya
- Dy, Grace K.
- Madden, Katherine G.
- Shirai, Keisuke
- Dragnev, Konstantin
- Tafe, Laura J.
- Zhu, Jason
- Labriola, Matthew
- Marin, Daniele
- McCall, Shannon J.
- Clarke, Jeffrey
- George, Daniel J.
- Zhang, Tian
- Zibelman, Matthew
- Ghatalia, Pooja
- Araujo-Fernandez, Isabel
- Cruz-Merino, Luis de la
- Singavi, Arun
- George, Ben
- MacKinnon, Alexander C.
- Thompson, Jonathan
- Singh, Rajbir
- Jacob, Robin
- Kasuganti, Deepa
- Shah, Neel
- Day, Roger
- Galluzzi, Lorenzo
- Gardner, Mark
- Morrison, Carl
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization
Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization